Mechanisms of pleural liquid formation in pleural inflammation

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 4, 1997, Pages 305-309

  Marchi, Evaldo ^a   Broaddus, V Courtney ^b  

^a Faculdade de Medicina de Jundal   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; AUTACOID; CHOLESTEROL;

HUMAN; PLEURA EFFUSION; REVIEW; TUBERCULOUS PLEURISY;

ADENOSINE DEAMINASE; CHOLESTEROL; HUMANS; INFLAMMATION MEDIATORS; PLEURAL EFFUSION; TUBERCULOSIS, PLEURAL;

EID: 0031179115     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199707000-00012     Document Type: Article

References (22)

1. Sasse SA, Causing LA, Mulligan ME, Light RW: Serial pleural fluid analysis in a new experimental model of empyema. Chest 1996, 109:1043-1048.
2. Kikuchi M, Tsuzurahara K, Suzuki T, Yato N, Naito K: Involvement of leukotrienes in allergic pleurisy in actively sensitized rats: inhibition by the lipoxygenase inhibitor T-0757 of the increase in vascular permeability and leukotriene E4 production. Inflamm Res 1996, 45:192-197.
3. Edamitsu S, Matsukawa A, Ohkawara S, Takagi K, Nariuchi H, Yoshinaga M: Role of TNFa, IL-1, and IL-1ra in the mediation of leukocyte infiltration and increased vascular permeability in rabbits with LPS-induced pleurisy. Clin Immunol Immunopathol 1995, 75:68-74.
4. Utsunomiya I, Ito M, Watanabe K, Tsurufuji S, Matsushima K, Oh-ishi S: Infiltration of neutrophils by intrapleural injection of tumour necrosis factor, interleukin-1, and interleukin-8 in rats, and its modification by actinomycin D. Br J Pharmacol 1996, 117:611-614.
5. Silva-Mejias C, Gamboa-Antiñolo F, Lopez-Cortés LF, Curz-Ruiz M, Pachon J: Interleukin-1β in pleural fluids of different etiologies: its role as inflammatory mediator in empyema. Chest 1995, 108:942-945.
6. Yanagawa H, Yano S, Haku T, Ohmoto Y, Sone S: Interleukin-1 receptor antagonist in pleural effusion due to inflammatory and malignant lung disease. Eur Respir J 1996, 9:1211-1216.
7. Yokoyama A, Kohno N, Fujino S, Abe M, Ishida O, Hiwada K: Soluble Interleukin-6 receptor levels in pleural effusions. Respir Med 1996, 90:329-332.
8. Ceyhan BB, Ozgun S, Celikel T, Yalcin M, Koc M: IL-8 in pleural effusion. Respir Med 1996, 90:215-221.
9. Henriques GMO, Miotla JM, Cordeiro RSB, Wolitzky BA, Woolley ST, Hellewell PG: Selectins mediate eosinophil recruitment in vivo: a comparison with their role in neutrophil influx. Blood 1996, 87:5297-5304. These authors have selectively inhibited selectins in a model of endotoxin-induced pleurisy in the mouse. Of note, blockade of P-selectin had a greater effect on eosinophil influx (approximately 40% decrease) than on neutrophil influx (approximately 20% decrease), suggesting the possibility of selective inhibition of eosinophil-induced allergic inflammatory processes.
10. Hoffman JC, Krüger H, Lührs J, Hamm H: Detection of soluble adhesion molecules in pleural effusions. Chest 1996, 110:107-113.
11. Burgess LJ, Maritz FJ, Le Roux I, Taljaard JJF: Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio: increased specificity for the diagnosis of tuberculous pleuritis. Chest 1996, 109:414-419.
12. Orphanidou D, Gaga M, Rasidakis A, Dimakou K, Toumbis M, Latsi P, Pandalos J, Christacopoulou J, Jordanoglou J: Tumour necrosis factor, interleukin-1 and adenosine deaminase in tuberculous pleural effusion. Respir Med 1996, 90:95-98.
13. Shibagaki T, Hasegawa Y, Saito H, Yanori S, Shimokata K: Adenosine deaminase isozymes in tuberculous pleural effusion. J Lab Clin Med 1996, 127:348-352.
14. 2, which has an unclear origin but does not appear to arise from lymphocytes. Further studies about this isoenzyme may illuminate important aspects of pathophysiology of tuberculous effusions.
15. Ferrer JS, Muñoz XG, Orriols RM, Light RW, Morell FB: Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. Chest 1996, 109:1508-1513. In a rare prospective study of idiopathic pleural effusions, 40 consecutive patients with undiagnosed exudative effusions were followed up for a mean of 62 months. Most (80%) were never diagnosed. Of interest, the authors use ADA to guide therapy; given that ADA concentration was low (< 45 IU/L) in their 19 patients with positive tuberculin tests, the patients were not treated with antituberculous therapy. None of the 19 patients with positive tuberculin developed active infection in the 36 to 108 months of follow-up.
16. Costa M, Quiroga T, Cruz E: Measurement of pleural fluid cholesterol and lactate dehydrogenase: a simple and accurate set of indicators for separating exudates from transudates. Chest 1995, 108:1260-1263.
17. Antony VB, Holm KA: Testing the waters: differentiating transudates from exudates. Chest 1995, 105:1191-1192.
18. Pfalzer B, Hamm H, Beisiegel U, Ostendorf P: Lipoproteins and apolipoproteins in human pleural effusions. J Lab Clin Med 1992, 120:483-493.
19. Romero S, Candela A, Arriero JM: Keep testing the waters [letter]. Chest 1996, 110:299.
20. Burgess LJ, Maritz FJ, Taljaard JJF: Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest 1995, 107:1604-1609.
21. Vives M, Porcel JM, de Vera MV, Ribelles E, Rubio M: A study of Light's criteria and possible modifications for distinguishing exudative from transudative pleural effusions. Chest 1996, 109:1503-1507.
22. Bartter T, Santarelli RJ, Pratter MR: Transudate vs exudate: genug! Chest 1996, 109:1419-1420. In this editorial, the authors make an impassioned plea to stop studying modifications of the Light's criteria for discrimination of transudates from exudates. They suggest a number of other avenues more worthy of study.